vs
Side-by-side financial comparison of Axon Enterprise (AXON) and BeOne Medicines Ltd. (ONC). Click either name above to swap in a different company.
BeOne Medicines Ltd. is the larger business by last-quarter revenue ($1.5B vs $796.7M, roughly 1.9× Axon Enterprise). BeOne Medicines Ltd. runs the higher net margin — 4.4% vs 0.3%, a 4.1% gap on every dollar of revenue. On growth, Axon Enterprise posted the faster year-over-year revenue change (38.9% vs 32.8%). BeOne Medicines Ltd. produced more free cash flow last quarter ($379.8M vs $155.4M). Over the past eight quarters, BeOne Medicines Ltd.'s revenue compounded faster (41.2% CAGR vs 31.5%).
Axon Enterprise, Inc. is an American company based in Scottsdale, Arizona, that develops weapons and technology products for military, law enforcement, and civilians.
BeOne Medicines Ltd.ONCEarnings & Financial Report
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
AXON vs ONC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $796.7M | $1.5B |
| Net Profit | $2.7M | $66.5M |
| Gross Margin | 57.9% | 90.5% |
| Operating Margin | -6.3% | 12.4% |
| Net Margin | 0.3% | 4.4% |
| Revenue YoY | 38.9% | 32.8% |
| Net Profit YoY | -98.0% | 143.8% |
| EPS (diluted) | $0.02 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $796.7M | $1.5B | ||
| Q3 25 | $710.6M | $1.4B | ||
| Q2 25 | $668.5M | $1.3B | ||
| Q1 25 | $603.6M | $1.1B | ||
| Q4 24 | $573.4M | $1.1B | ||
| Q3 24 | $544.3M | $1.0B | ||
| Q2 24 | $504.1M | $929.2M | ||
| Q1 24 | $460.7M | $751.7M |
| Q4 25 | $2.7M | $66.5M | ||
| Q3 25 | $-2.2M | $124.8M | ||
| Q2 25 | $36.1M | $94.3M | ||
| Q1 25 | $88.0M | $1.3M | ||
| Q4 24 | $136.0M | $-151.9M | ||
| Q3 24 | $67.0M | $-121.3M | ||
| Q2 24 | $40.8M | $-120.4M | ||
| Q1 24 | $133.2M | $-251.2M |
| Q4 25 | 57.9% | 90.5% | ||
| Q3 25 | 60.1% | 86.1% | ||
| Q2 25 | 60.4% | 87.5% | ||
| Q1 25 | 60.6% | 85.2% | ||
| Q4 24 | 60.5% | 85.8% | ||
| Q3 24 | 60.8% | 83.0% | ||
| Q2 24 | 60.3% | 85.1% | ||
| Q1 24 | 56.4% | 83.4% |
| Q4 25 | -6.3% | 12.4% | ||
| Q3 25 | -0.3% | 11.5% | ||
| Q2 25 | -0.2% | 6.7% | ||
| Q1 25 | -1.5% | 1.0% | ||
| Q4 24 | -2.6% | -7.0% | ||
| Q3 24 | 4.4% | -12.0% | ||
| Q2 24 | 6.5% | -11.5% | ||
| Q1 24 | 3.5% | -34.8% |
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | -0.3% | 8.8% | ||
| Q2 25 | 5.4% | 7.2% | ||
| Q1 25 | 14.6% | 0.1% | ||
| Q4 24 | 23.7% | -13.5% | ||
| Q3 24 | 12.3% | -12.1% | ||
| Q2 24 | 8.1% | -13.0% | ||
| Q1 24 | 28.9% | -33.4% |
| Q4 25 | $0.02 | $0.05 | ||
| Q3 25 | $-0.03 | $0.08 | ||
| Q2 25 | $0.44 | $0.06 | ||
| Q1 25 | $1.08 | $0.00 | ||
| Q4 24 | $1.68 | $-0.10 | ||
| Q3 24 | $0.86 | $-0.09 | ||
| Q2 24 | $0.53 | $-0.09 | ||
| Q1 24 | $1.73 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.7B | $4.5B |
| Total DebtLower is stronger | $1.8B | $836.4M |
| Stockholders' EquityBook value | $3.2B | $4.4B |
| Total Assets | $7.0B | $8.2B |
| Debt / EquityLower = less leverage | 0.56× | 0.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7B | $4.5B | ||
| Q3 25 | $2.4B | $4.0B | ||
| Q2 25 | $2.1B | $2.8B | ||
| Q1 25 | $2.2B | $2.5B | ||
| Q4 24 | $788.1M | $2.6B | ||
| Q3 24 | $1.0B | $2.7B | ||
| Q2 24 | $968.9M | $2.6B | ||
| Q1 24 | $964.1M | $2.8B |
| Q4 25 | $1.8B | $836.4M | ||
| Q3 25 | $2.0B | — | ||
| Q2 25 | $2.0B | — | ||
| Q1 25 | $2.0B | — | ||
| Q4 24 | $680.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $3.2B | $4.4B | ||
| Q3 25 | $3.0B | $4.1B | ||
| Q2 25 | $2.7B | $3.8B | ||
| Q1 25 | $2.6B | $3.5B | ||
| Q4 24 | $2.3B | $3.3B | ||
| Q3 24 | $2.1B | $3.4B | ||
| Q2 24 | $1.9B | $3.4B | ||
| Q1 24 | $1.8B | $3.4B |
| Q4 25 | $7.0B | $8.2B | ||
| Q3 25 | $6.7B | $7.6B | ||
| Q2 25 | $6.2B | $6.3B | ||
| Q1 25 | $6.1B | $5.8B | ||
| Q4 24 | $4.5B | $5.9B | ||
| Q3 24 | $4.0B | $5.8B | ||
| Q2 24 | $3.7B | $5.7B | ||
| Q1 24 | $3.6B | $5.7B |
| Q4 25 | 0.56× | 0.19× | ||
| Q3 25 | 0.66× | — | ||
| Q2 25 | 0.73× | — | ||
| Q1 25 | 0.79× | — | ||
| Q4 24 | 0.29× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $217.2M | $417.3M |
| Free Cash FlowOCF − Capex | $155.4M | $379.8M |
| FCF MarginFCF / Revenue | 19.5% | 25.4% |
| Capex IntensityCapex / Revenue | 7.8% | 2.5% |
| Cash ConversionOCF / Net Profit | 79.14× | 6.28× |
| TTM Free Cash FlowTrailing 4 quarters | $75.1M | $941.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $217.2M | $417.3M | ||
| Q3 25 | $60.0M | $402.6M | ||
| Q2 25 | $-91.7M | $263.6M | ||
| Q1 25 | $25.8M | $44.1M | ||
| Q4 24 | $250.2M | $75.2M | ||
| Q3 24 | $91.3M | $188.4M | ||
| Q2 24 | $82.8M | $-95.6M | ||
| Q1 24 | $-15.9M | $-308.6M |
| Q4 25 | $155.4M | $379.8M | ||
| Q3 25 | $33.4M | $354.5M | ||
| Q2 25 | $-114.7M | $219.8M | ||
| Q1 25 | $932.0K | $-12.3M | ||
| Q4 24 | $225.4M | $-17.3M | ||
| Q3 24 | $64.8M | $54.7M | ||
| Q2 24 | $71.4M | $-205.5M | ||
| Q1 24 | $-32.1M | $-465.1M |
| Q4 25 | 19.5% | 25.4% | ||
| Q3 25 | 4.7% | 25.1% | ||
| Q2 25 | -17.2% | 16.7% | ||
| Q1 25 | 0.2% | -1.1% | ||
| Q4 24 | 39.3% | -1.5% | ||
| Q3 24 | 11.9% | 5.5% | ||
| Q2 24 | 14.2% | -22.1% | ||
| Q1 24 | -7.0% | -61.9% |
| Q4 25 | 7.8% | 2.5% | ||
| Q3 25 | 3.7% | 3.4% | ||
| Q2 25 | 3.4% | 3.3% | ||
| Q1 25 | 4.1% | 5.0% | ||
| Q4 24 | 4.3% | 8.2% | ||
| Q3 24 | 4.9% | 13.3% | ||
| Q2 24 | 2.2% | 11.8% | ||
| Q1 24 | 3.5% | 20.8% |
| Q4 25 | 79.14× | 6.28× | ||
| Q3 25 | — | 3.22× | ||
| Q2 25 | -2.54× | 2.79× | ||
| Q1 25 | 0.29× | 34.71× | ||
| Q4 24 | 1.84× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 2.03× | — | ||
| Q1 24 | -0.12× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXON
| Software And Sensors Segment | $342.5M | 43% |
| TASER Devices Professional | $264.2M | 33% |
| Personal Sensors | $109.1M | 14% |
| Platform Solutions | $80.9M | 10% |
ONC
Segment breakdown not available.
